Experienced in Liposarcoma

Dr. Regina J. Brown

Oncology | Hematology Oncology
2121 East Harmony Road, 150, 
Fort Collins, CO 
Experienced in Liposarcoma
2121 East Harmony Road, 150, 
Fort Collins, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Regina Brown is an Oncologist and a Hematologist Oncology provider in Fort Collins, Colorado. Dr. Brown is rated as an Experienced provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Paget Disease of the Breast, Intraductal Papilloma, Inflammatory Breast Cancer, and Angiosarcoma.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in CO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2121 East Harmony Road, 150, Fort Collins, CO 80528
Other Locations
12605 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: May 14, 2021
Intervention Type: Drug
Study Drug: Fulvestrant with Enzalutamide
Study Phase: Phase 2
View 4 Less Clinical Trials

5 Total Publications

Multidisciplinary Approach to Treatment of Advanced Basal Cell Carcinoma With Involvement of the Left Orbit.
Multidisciplinary Approach to Treatment of Advanced Basal Cell Carcinoma With Involvement of the Left Orbit.
Journal: Journal of drugs in dermatology : JDD
Published: June 04, 2024
Similar Doctors
Elite in Liposarcoma
Dr. Breelyn Wilky
Hematology Oncology | Oncology
Elite in Liposarcoma
Dr. Breelyn Wilky
Hematology Oncology | Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (54.9 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Breelyn Wilky is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Wilky is rated as an Elite provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Liposarcoma.

Elite in Liposarcoma
Dr. Anthony D. Elias
Oncology
Elite in Liposarcoma
Dr. Anthony D. Elias
Oncology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
 (54.8 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Elias is an Oncologist in Aurora, Colorado. Dr. Elias is rated as an Elite provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Breast Cancer, Adult Soft Tissue Sarcoma, Liposarcoma, and Inflammatory Breast Cancer. Dr. Elias is currently accepting new patients.

Distinguished in Liposarcoma
Dr. Ioana M. Hinshaw
Hematology Oncology | Hematology | Oncology
Distinguished in Liposarcoma
Dr. Ioana M. Hinshaw
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

1800 Williams St, Suite 200, 
Denver, CO 
 (53.8 miles away)
303-388-4876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ioana Hinshaw is a Hematologist Oncology specialist and a Hematologist in Denver, Colorado. Dr. Hinshaw is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Bone Tumor, Adult Soft Tissue Sarcoma, Paget Disease of the Breast, and Myxoid Liposarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brown's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile